This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revision | Next revisionBoth sides next revision | ||
home:food:aim_health:aging [02.12.2019] – [with additional studies] sallieq | home:food:aim_health:aging [02.12.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 18: | Line 18: | ||
Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pubmed> | Replacing candesartan with olmesartan decreased LVMI in association with a sustained decrease of plasma Ang II over a 12-month period without changing blood pressure or plasma aldosterone in patients with essential hypertension. (({{pubmed> | ||
- | (({{pubmed> | + | Inhibition of renin-angiotensin system attenuates periadventitial inflammation and reduces atherosclerotic lesion formation. |
Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> | Therapeutic and supratherapeutic OLM doses had no clinically significant effect on cardiac repolarization and were well tolerated. (({{pubmed> |